Andere talen Xilio Therapeutics, Inc.

Aandelen

XLO

US98422T1007

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,15 ^USD	-10,16%		-2,54%	+109,09%

01/04	Xilio Therapeutics, Inc. rapporteert winstresultaten voor het vierde kwartaal eindigend op 31 december 2023	CI
01/04	Xilio Therapeutics, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	19/04
Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/04
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results	01/04
Xilio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Sector Update: Health Care Stocks Slide Late Afternoon	01/04
Top Midday Gainers	01/04
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures	01/04
Top Premarket Gainers	01/04
Xilio Shares Take Flight Premarket After Gilead Deal	28/03
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	28/03
Xilio Therapeutics : Corporate Update Call	28/03
Gilead Sciences Signs Exclusive Development, Commercialization License for Xilio's Tumor-Activated IL-12	28/03
Xilio Therapeutics Plans Private Placement, Job Cuts	28/03
Gilead Sciences in Exclusive License for Xilio Tumor-Activated IL-12 Program	28/03
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing	28/03
Xilio Therapeutics, Inc. Enters Exclusive License Agreement with Gilead Sciences, Inc	28/03
Xilio Therapeutics, Inc. Plans Workforce Reduction	28/03
Xilio Therapeutics, Inc. Reports Additional Data from Its Phase 2 Clinical Trial Evaluating XTX202	28/03
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program	28/03
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program	28/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Xilio Therapeutics, Inc.

Aandelen

XLO

US98422T1007

Andere talen

Filters